Relay Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Relay Therapeutics has a total shareholder equity of $752.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $844.0M and $92.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$750.09m |
| Equity | US$752.00m |
| Total liabilities | US$91.98m |
| Total assets | US$843.98m |
Recent financial health updates
We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth
Nov 14
Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?
Jun 08Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Feb 22Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Oct 23Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business
Mar 26Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business
Dec 08
Recent updates
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%
Apr 17Relay Therapeutics: Platform More Important Than Programs
Mar 13Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag
Feb 13Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)
Jan 21We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth
Nov 14Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?
Jun 08Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Feb 22Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Oct 23Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts
Sep 30Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform
Sep 18Why did Relay Therapeutics stock drop today?
Sep 09Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)
Jan 02Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year
Aug 17Relay Therapeutics, Inc. (NASDAQ:RLAY) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 16Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business
Mar 26Read This Before Selling Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares
Feb 01Relay Therapeutics inks deal for RLY-1971 with Genentech
Dec 14Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business
Dec 08Relay Therapeutics reports Q3 results
Nov 12Financial Position Analysis
Short Term Liabilities: RLAY's short term assets ($770.1M) exceed its short term liabilities ($30.3M).
Long Term Liabilities: RLAY's short term assets ($770.1M) exceed its long term liabilities ($61.7M).
Debt to Equity History and Analysis
Debt Level: RLAY is debt free.
Reducing Debt: RLAY has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RLAY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RLAY has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 38.9% each year.